Reviva Pharmaceuticals Holdings, Inc. filed a definitive proxy statement on November 9, 2026, calling stockholders to vote on five proposals at an annual meeting scheduled for December 18, 2026, including a potential reverse stock split at a ratio ranging from 1:2 to 1:100.

Key Highlights

  • Annual meeting date: December 18, 2026 at 11:00 a.m. Pacific Time, held virtually via the Internet.
  • Reverse split proposal: Stockholders will vote on authorizing a reverse stock split of issued common shares at a ratio ranging from one-for-two (1:2) to one-for-one hundred (1:100), implementable at any time prior to December 31, 2027, at the Board's sole discretion.
  • Prior reverse split: According to the filing, a one-for-twenty (1:20) reverse stock split was implemented on March 9, 2026, and all share amounts in the proxy statement have been retrospectively adjusted to reflect that event.
  • Record date: Only stockholders of record at the close of business on October 30, 2026 are entitled to vote.
  • Auditor ratification: Stockholders will vote on ratifying Baker Tilly US, LLP as independent registered public accounting firm for the year ending December 31, 2026.
  • Director election: Five director nominees are proposed to serve until the next annual meeting of stockholders.
  • Say-on-Pay: An advisory vote on executive compensation of named executive officers is included on the agenda.

Reviva Pharmaceuticals Puts Broad Reverse Split Authority to Stockholder Vote

Reviva Pharmaceuticals Holdings, Inc., a pharmaceutical company headquartered in Cupertino, California, filed a definitive proxy statement with the SEC on November 9, 2026, in connection with its 2026 Annual Meeting of Stockholders. The filing discloses that the company intends to begin distributing the proxy notice, proxy statement, 2025 Annual Report on Form 10-K, and proxy card to stockholders on or about November 9, 2026. The company operates under its 2020 Equity Incentive Plan and 2006 Equity Incentive Plan, both referenced in the proxy's equity compensation disclosures.

The most consequential proposal before stockholders is the Reverse Stock Split Proposal, which would authorize the Board of Directors to amend the Certificate of Incorporation and implement a reverse split of issued common shares at any ratio between 1:2 and 1:100. According to the filing, the Board would retain sole discretion over whether to proceed with the split and, if so, at which specific ratio within the authorized range, without requiring any additional stockholder approval. The authorization, if granted, would remain available until December 31, 2027. The filing also notes that a 1:20 reverse split was already carried out on March 9, 2026, and all share and per-share figures in the proxy have been retrospectively adjusted accordingly.

Beyond the reverse split vote, the agenda includes the election of five directors, ratification of Baker Tilly US, LLP as the independent auditor for fiscal year 2026, an advisory say-on-pay vote on named executive officer compensation, and an adjournment proposal to allow additional proxy solicitation if needed. The Board of Directors, according to the filing, recommends a vote in favor of all five proposals. Stockholders may vote by Internet, telephone, or mail, and those who attend the virtual annual meeting may cast their votes during the meeting even if they have already submitted a proxy.

What Was Disclosed

Reviva Pharmaceuticals filed a definitive proxy statement covering its December 18, 2026 annual stockholder meeting. The filing presents five proposals, with the reverse stock split authorization at ratios up to 1:100 representing the most significant structural matter on the agenda.